Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Industry

8 Mar 2023

A Deeper Look at atai Life Sciences’ Corporate Update

atai Life Science has released its most recent corporate update, an opportunity to take a step back and see the full breadth of atai’s diverse set of programs....

By Microdose NewsDesk

Industry

7 Mar 2023

Small Pharma Announces Additional Positive Data From Phase 2a Trial

Today, both patients and investors received additional good news, as Small Pharma has reported supportive data to corroborate its initial Phase 2 trial topline results....

By Microdose NewsDesk

Don’t Miss

7 Mar 2023

News You Might Have Missed: March 7th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Don’t Miss

27 Feb 2023

News You Might Have Missed: Feb 27th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Finance

24 Feb 2023

Transcend Therapeutics Announces $40 million Series A Funding

Transcend Therapeutics, a mental health-focused biotechnology company, announces Series A funding round of $40 million led by Alpha Wave Global and Integrated Investment Partners...

By Microdose NewsDesk

Culture

22 Feb 2023

John Oliver Covers Psychedelics on Last Week Tonight

Emmy-award winning talk show host John Oliver has devoted his entire segment to psychedelic therapy....

By Microdose NewsDesk

Industry

15 Feb 2023

Small Pharma Doses First Patient in DMT Phase I Trial

Small Pharma Doses First Patient in DMT Phase I Trial....

By Microdose NewsDesk

Law & Politics

15 Feb 2023

Decrim Update: Arizona Unanimously Approves Psilocybin Research Bill

Arizona, a historically conservative state, has just approved a bill to research psilocybin mushrooms for therapeutic purposes....

By Microdose NewsDesk

Finance

14 Feb 2023

Cybin Reports Q3 Financial Results and Business Highlights

Cybin has released its Q3 financial results and business highlights....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.